Literature DB >> 35913672

Access to Surgical Treatment for Breast Cancer in the Philippines.

Luis Miguel B Co1, Edward Christopher Dee2, Michelle Ann B Eala3, Samuel D Ang4, Christian Daniel U Ang5,6.   

Abstract

Female breast cancer is the most commonly diagnosed cancer worldwide; however, while high-income countries have the highest incidence rates, lower-middle income countries have the highest mortality rates. In this article, we describe the landscape of disparities in access to surgical care for patients with breast cancer in the Philippines, a lower-middle income country in Southeast Asia. We describe the payment landscape that allows access to care for patients with non-metastatic disease, and draw attention to the fact that despite some degree of insurance for most Filipinos, great barriers to access remain in the form of a low number of surgical providers, geographic disparities, and persistent socioeconomic barriers. Lastly, we suggest steps forward to improve equity in access to surgical care for Filipino patients with breast cancer.
© 2022. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2022        PMID: 35913672      PMCID: PMC9341402          DOI: 10.1245/s10434-022-12311-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   4.339


Female breast cancer is the most commonly diagnosed cancer worldwide;[1] however, while high-income countries have the highest incidence rates, lower-middle income countries (LMIC) have the highest mortality rates. In the Philippines, a lower-middle income country in Southeast Asia (SEA), this inequity has been magnified during the coronavirus disease 2019 (COVID-19) pandemic where access to and willingness to seek treatment have been reduced due to fear of being infected, lockdowns preventing patients from traveling to healthcare facilities, and unemployment reducing purchasing power and demand for healthcare.[2] Under the Z Benefit Package of the country’s national health insurance system, Filipinos diagnosed with stage 0–IIIA breast cancer are entitled to coverage of all necessary materials and services needed for the entire course of their treatment.[3] This includes payment for hospital room fees, drugs and laboratory examinations, operating room and professional fees, and other services. However, despite this coverage provided by the government, access to surgical management is limited in rural and geographically isolated areas due to the lack of and unequal distribution of health facilities and providers across the country. The Philippines has 0.9 surgeons per 100,000 people, far below the recommended number of 20 specialist surgical, anesthetic, and obstetric (SAO) physicians supported by the Lancet Commission on Global Surgery.[4] In addition, patients residing in Luzon, where the capital Manila is located, have greater access to surgical facilities, as 58% of the country’s equipped government hospitals are located there, compared with Mindanao (24%) and Visayas (18%).[5] Improving health financing is critical. A study conducted on countries in SEA showed that over 30% of patients with cancer are at risk of financial catastrophe, with women being at greatest risk.[6] Although the Z Benefit Package covers all costs for patients with non-metastatic breast cancer, patients with metastatic cancer, who are likely to incur higher out-of-pocket costs, are not covered. Non-medical costs, including childcare, transportation, accommodation, and loss of income and productivity during and after treatment, must also be taken into consideration as they impact health-seeking behavior and willingness to undergo treatment. Therefore, it is important to expand national health insurance coverage and increase funding for patients with cancer. This will require a substantial increase in the national health budget; currently, the Philippine government has allotted only 1.2% of the country's gross domestic product (GDP) for health, far below the WHO-recommended 5%. Indeed, Duggan et al.[7] found that the degree of universal health coverage and access to care such as having public cancer centers are predictors of a country’s capacity to reduce breast cancer mortality. Therefore, breast cancer mortality in the Philippines is not likely to change until these two areas are addressed through the public healthcare system. Capacity-building and development of public health facilities across all regions of the country must be prioritized, as countries with a higher number of public cancer centers have improved breast cancer mortality.[8] Efforts are underway to create cancer centers in the country; however, access especially for geographically isolated patients is critical. Furthermore, the referral system from primary to specialized health care units requires efforts to further streamline organization. A nationwide telemedicine system and electronic medical record system may help facilitate these improvements. Additionally, adherence to breast cancer screening, diagnosis, and treatment may be poor among Filipino women due to cultural barriers.[9] This may be mitigated through culturally appropriate community education and public health campaigns to help patients understand the importance of early detection and treatment to improve breast cancer outcomes. The surgical workforce must also be increased and equitably distributed. Using the projected Philippine population, the Philippines will need to increase its SAO workforce to 25,200 to satisfy the recommended density of 20 per 100,000 people. This should also be supported by increasing the density and distribution of allied health providers such as nurses, operational managers, and radiology, pathology, and laboratory technicians.[4] Financial incentives are needed to encourage specialists to practice in underserved areas. A multifaceted approach is needed to increase the rural medical workforce in Asia-Pacific LMICs through increasing publicly-funded universities, promoting education access in rural communities, developing scholarships for trainees from rural and underrepresented regions, and ensuring having a supportive and well-financed rural health system.[10] In addition, collaboration with other oncology disciplines may aid in enacting other needed changes, such as government procurement and local production of essential drugs, as well as increasing coverage for treatment in private facilities. Therefore, government legislation is crucial to making treatment equitable regardless of a patient's socioeconomic standing and geographic location.
  5 in total

1.  Outcome of screening by clinical examination of the breast in a trial in the Philippines.

Authors:  Paola Pisani; D M Parkin; Corazon Ngelangel; Divina Esteban; Lorna Gibson; Marilou Munson; Mary Grace Reyes; Adriano Laudico
Journal:  Int J Cancer       Date:  2006-01-01       Impact factor: 7.396

2.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 3.  Factors associated with increasing rural doctor supply in Asia-Pacific LMICs: a scoping review.

Authors:  Likke Prawidya Putri; Belinda Gabrielle O'Sullivan; Deborah Jane Russell; Rebecca Kippen
Journal:  Hum Resour Health       Date:  2020-12-01

4.  The Impact of COVID-19 on Hospital Admissions for Twelve High-Burden Diseases and Five Common Procedures in the Philippines: A National Health Insurance Database Study 2019-2020.

Authors:  Jhanna Uy; Vanessa T Siy Van; Valerie Gilbert Ulep; Diana Beatriz Bayani; Damian Walker
Journal:  Lancet Reg Health West Pac       Date:  2021-11-03
  5 in total
  1 in total

1.  Improving cancer care in the Philippines: The need for deliberate and careful implementation of the National Integrated Cancer Control Act.

Authors:  Edward Christopher Dee; Christian Daniel U Ang; Frederic Ivan L Ting; Enrico D Tangco; Michelle Ann B Eala
Journal:  Lancet Reg Health West Pac       Date:  2022-10-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.